Nuwellis (NUWE) Set to Release Earnings on Wednesday

Nuwellis (NASDAQ:NUWE) is expected to be posting its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($122.85) per share and revenue of $2.50 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:00 AM ET.

Nuwellis (NASDAQ:NUWE) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($239.76) earnings per share for the quarter, missing the consensus estimate of ($214.20) by ($25.56). The firm had revenue of $1.97 million for the quarter, compared to analyst estimates of $2.42 million. Nuwellis had a negative return on equity of 623.14% and a negative net margin of 123.38%.

Nuwellis Stock Performance

NASDAQ:NUWE opened at $5.91 on Wednesday. The company has a market cap of $3.19 million, a PE ratio of -0.00 and a beta of 0.03. Nuwellis has a 52-week low of $2.52 and a 52-week high of $1,556.07. The stock has a 50-day simple moving average of $6.46 and a 200 day simple moving average of $235.12.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Wall Street Zen upgraded Nuwellis to a “hold” rating in a research note on Saturday, July 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nuwellis in a research note on Monday, September 21st. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Nuwellis

Nuwellis, Inc is a medical device company focused on fluid management therapies for patients with fluid overload. The company develops and commercializes ultrafiltration technologies designed to remove excess salt and fluid from the blood when conventional diuretic therapy may be inadequate or poorly tolerated.

Nuwellis’ principal product is the Aquadex system, including the Aquadex FlexFlow system, a compact ultrafiltration platform used in hospital settings. The system is intended for temporary extracorporeal fluid removal in patients with conditions such as fluid overload associated with heart failure, renal dysfunction, and other critical-care needs.